New research indicates that 3-D cell culturing technology developed by Rainbow Coral Corp. (OTCBB: RBCC) partner Nano 3D BioSciences (n3D) could make toxicity tests for airborne chemicals faster and more effective than ever before.
In collaboration with scientists at Rice University, Dr. Glauco Souza of n3D led a research study that demonstrates the potential of the company’s magnetic levitation tech to grow some of the most realistic lung tissue produced in a laboratory. In the study, researchers combined four types of human cells to replicate three-dimensional tissues from the wall of the bronchiole, found deep inside the lung.
Using traditional 2-D cell cultures, producing cells at the air-liquid interface, ideal for toxicity testing, is enormously difficult. Using n3D technology, however, researchers were able to magnetically levitate bronchiole tissue to the air-liquid interface so that airborne toxins can be exposed to the epithelial layer of the tissue, just as would occur in human lungs.
The same methods have also been used to culture heart valve tissue. RBCC believes that its joint venture partner’s technology is on the cusp of becoming standard equipment in cellular research labs around the globe.
“Scientists everywhere are discovering that n3D’s Bio-Assembler technology can produce superior cell cultures for a broad range of research fields,” said RBCC CEO Patrick Brown. “As more and more high-profile cell researchers discover this system’s potential, the market for the technology will continue to grow exponentially.”
The Bio-Assembler’s fusion of magnetic levitation and nanoparticle assembly technology allows it to produce accurate, 3D representations of in vivo tissues faster and easier than any other existing tools. The incredible device is key to RBCC’s plans to participate in the impressive upside in store for n3D.
“Previously, when I worked at Baylor College of Medicine, we used transwells to study human bronchial epithelial cells,” said n3D scientist Jacob Gage, who co-authored the bronchiole study. “After switching to the Bio-Assembler, we were able to culture multiple cell types to generate an in vivo-like environment. This gave us the opportunity to create truly three-dimensional and histologically accurate structures.”
For more information on Rainbow BioSciences, please visit www.rainbowbiosciences.com/investors.html.
Rainbow BioSciences will develop new medical and research technology innovations to compete alongside companies such as Bristol Myers Squibb Co. (NYSE: BMY), Biogen Idec Inc. (NASDAQ: BIIB), Abbott Laboratories (NYSE: ABT) and Amgen, Inc. (NASDAQ: AMGN).
About Rainbow BioSciences
Rainbow BioSciences, LLC, is a wholly owned subsidiary of Rainbow Coral Corp. (OTCBB: RBCC). The company continually seeks out new partnerships with biotechnology developers to deliver profitable new medical technologies and innovations. For more information on our growth-oriented business initiatives, please visit our website at [www.RainbowBioSciences.com]. For investment information and performance data on the company, please visit www.RainbowBioSciences.com/investors.html.
Notice Regarding Forward-Looking Statements
Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995: This news release contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, including statements that include the words "believes," "expects," "anticipate" or similar expressions. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of the company to differ materially from those expressed or implied by such forward-looking statements. In addition, description of anyone's past success, either financial or strategic, is no guarantee of future success. This news release speaks as of the date first set forth above and the company assumes no responsibility to update the information included herein for events occurring after the date hereof.